Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

PHAR Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Pharming Group N.V.NASDAQ: PHAR

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash turns negative

Q1 FY2026 net change in cash was -$92.96M, compared with $5.15M a year earlier. Trailing-twelve-month net change in cash was -$9.72M. Over 3 fiscal years it compounded at +80.8% a year.

Context

  • Net change in cash amounted to 24.2% of revenue in FY2025, up 21.9 pp from a year earlier.
  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near -$92.96M or moves back toward the trailing-twelve-month quarterly average of -$2.43M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$92.96M-815.0% QoQ
Last fiscal yearDec 2025
$91.09M+1394.3% YoY
LTMMar 2026
-$9.72M-218.5% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1905.4%——
1 year+1394.3%——
3-year CAGR+80.8%——
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
91.09M USD
Year-over-year change
+1394.3%

Net Change in Cash vs competitors

How PHAR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -218.5% is the 5th highest of 9, against a peer median of -217.2%.
  • Net change in cash amounts to 2.6% of revenue for PHAR, versus a peer median of 71.5%.
PHAR Competitors
Net Change in Cash for PHAR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$734.76B USD+127759.4%+39.0%71.5%
STOKStoke Therapeutics, Inc.LTM Mar 2026$116.23M USD-220.5%+11.8%362.3%
SLNSilence Therapeutics plcLTM Mar 2026$59.21M USD—+49.3%6425.7%
PRQRProQR Therapeutics N.V.LTM Mar 2026€53.17M EUR-213.8%-24.9%395.5%
PHVSPharvaris N.V.LTM Sep 2026€52.24M EUR-316.8%——
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$42.04M USD-1225.2%—4.4%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$21.41M USD-320.3%-20.0%2.3%
PHARPharming Group N.V.LTM Mar 2026$9.72M USD-218.5%+80.8%2.6%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$465K USD+101.2%—0.7%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$221K USD-101.5%-2.2%—
Peer median (excluding PHAR) —-217.2%+4.8%71.5%

Competitors are the stored peer set for PHAR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income26.16M14.99M(12.01M)(8.79M)2.86M
Depreciation & Amortization22.23M13.19M15.93M16.64M0
Deferred Income Tax00000
Stock-Based Compensation10.27M6.39M9.25M11.65M0
Change in Working Capital(5.62M)(387K)(16.96M)(10.43M)14.4M
Accounts Receivables6.71M2.36M(18.54M)(7.02M)(3.36M)
Inventory(6.98M)(15.02M)(14.43M)(520.85K)(1.29M)
Accounts Payables000017.87M
Other Working Capital(5.36M)12.27M16.01M(2.88M)1.19M
Other Non-Cash Items(10.14M)(11.72M)(13.51M)(10.92M)32.8M
Operating Cash Flow42.9M22.46M(17.3M)(1.86M)50.07M
Capital Expenditures(18.95M)(1.98M)(1.46M)(824.25K)(751.09K)
Acquisitions (Net)07.3M00(65.53M)
Purchases of Investments(5.2M)0(382.01M)(294.4M)0
Sales of Investments00232.81M327.97M0
Other Investing Activities0021.28M084.72M
Investing Cash Flow(24.15M)5.32M(129.39M)32.74M18.43M
Debt Repayment(3.65M)(3.31M)(4.04M)(35.61M)0
Common Stock Issued5.35M2.28M0019.87M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(33.39M)(3.95M)3M(19.67K)(5.39M)
Financing Cash Flow(31.68M)(4.98M)(1.04M)(35.63M)14.48M
Effect of Forex Changes(2.07M)(7.38M)2.13M(2.29M)8.12M
Net Change in Cash(15M)15.42M(145.6M)(7.04M)91.09M
Free Cash Flow23.95M20.48M(18.77M)(2.68M)49.31M

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.